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A B S T R A C T
Background
Umbilical venous catheters are often used in unwell neonates. Infection related to the use of these catheters may cause significant
morbidity and mortality. The use of prophylactic antibiotics has been advocated for newborns with umbilical venous catheters in order
to reduce the risk of colonisation and acquired infection. Countering this is the possibility that harm may outweigh benefit. Prophylactic
antibiotics may be effective in preventing catheter-related blood stream infection, but may have the undesirable effect of promoting
the emergence of resistant strains of micro-organisms. A policy of prophylactic antibiotic use should take into account this possibility,
and has been used as a basis for arguing against its implementation.
Objectives
The primary objective was to assess whether prophylactic antibiotics, in neonates with umbilical venous catheters, reduce mortality
and morbidity. In separate comparisons, we planned to review two different policies regarding the prophylactic use of antibiotics in
neonates with umbilical venous catheters: 1) Among neonates with umbilical venous catheters, a policy of prophylactic antibiotics for
the duration of catheterisation (or other fixed duration of antibiotic treatment) versus placebo or no treatment; 2) Among neonates
with umbilical venous catheters who had been started on antibiotics at the time of catheterisation, but whose initial cultures to rule
out sepsis are negative, a policy of continuing versus discontinuing prophylactic antibiotics.
Search strategy
We searched MEDLINE (January 1966 to April 2005), CINAHL (1982 to April 2005), the Cochrane Central Register of Controlled
Trials (CENTRAL, The Cochrane Library, Issue 1, 2005).
Selection criteria
Randomised controlled trials or quasi-randomised trials in which newborn infants with umbilical venous catheters are randomised to
receive prophylactic antibiotics versus placebo or no treatment.
Data collection and analysis
Two reviewers independently assessed trial quality.
Main results
One study, of poor quality, met the criteria for inclusion in this review. Twenty-nine term infants, who had umbilical venous catheters
inserted specifically for transfusion procedures for hyperbilirubinaemia or polycythaemia, allocated non-randomly (quasi-randomised -
alternate allocation) to treatment (n = 15) or control (n = 14) groups. Those in the treatment group received penicillin and gentamicin
for three days. 5/15 infants given antibiotics and 5/14 control infants having positive blood cultures three days after catheter insertion.
All positive blood cultures were considered contaminated, due to lack of corroborating clinical and haematological evidence of infection.
Therefore, no infants were identified with evidence of septicaemia.
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Authors’ conclusions
There is insufficient evidence from randomised trials to support or refute the use of prophylactic antibiotics when umbilical venous
catheters are inserted in newborn infants. There is no evidence to support or refute continuing antibiotics once initial cultures rule out
infection in newborn infants with umbilical venous catheters.
P L A I N L A N G U A G E S U M M A R Y
There is insufficient evidence from randomised trials to either support or refute the routine use of preventive antibiotics in newborn
babies with umbilical vein catheters.
Sick newborn babies occasionally require the insertion of an umbilical vein catheter (a special tube) that goes into the vein in the
umbilicus (belly button). This allows fluid and medicines to be given. Some people believe that antibiotics should be given to all babies
with umbilical vein catheters in order to reduce the chance of infection occurring. However, antibiotics can have unwanted effects.
The reviewers found insufficient evidence to either support or refute the routine use of antibiotics for all babies with umbilical vein
catheters.
B A C K G R O U N D
Umbilical venous catheters are commonly used in the manage-
ment of newborn infants who are preterm or have other poten-
tially life-threatening illness. The use of central venous catheters
is recognised as a risk factor for nosocomial infection (Adams-
Chapman 2002; Chien 2002; Nagata 2002; Stoll 2002). It is un-
clear whether umbilical venous catheters are an independent risk
factor for late-onset sepsis. Stoll (Stoll 2002) analysed numerous
factors in a multivariate model and did not find umbilical venous
catheters to be an independent significant risk. However, Chien
(Chien 2002), on behalf of the Canadian Neonatal Network, con-
cluded that umbilical venous catheters are a significant risk factor.
Hyperalimentation with parenteral nutrition is an indication for
the use of umbilical venous catheters, and is also a risk factor for
nosocomial infection (Adams-Chapman 2002). Nosocomial in-
fection may cause significant morbidity and mortality (Stoll 2002).
Morbidity may include increased duration of respiratory illness,
including chronic lung disease, and need for respiratory support
(Stoll 2002; Ogawa 1999); increased length of hospital stay (Stoll
2002; Isaacs 2003); and impaired neurodevelopmental outcome
(Stoll 2004). The extent of the problem of infection related to um-
bilical venous catheters is largely unknown due to the widespread
use of antibiotics in the population of infants who have umbilical
venous catheters.
Patients requiring umbilical venous catheters may, by virtue of
their underlying illness, have impaired defence mechanisms - both
local and systemic. Prematurity is recognised as a risk factor for
late onset sepsis (Dear 1999). Preterm neonates are at high risk
of infection because of impaired immunity and umbilical venous
catheters may further increase this risk because they are foreign
bodies.
It is common practice in neonatal units to start antibiotics in in-
fants with respiratory distress and suspected infection, or in those
delivered following pre-term labour. Many of these infants will
have an umbilical venous catheter inserted. It is not clear whether
antibiotics should be discontinued if no infection is proven. It has
been common practice in some neonatal units that if the infant
has an umbilical venous catheter then antibiotics be continued in
order to reduce the rate of colonisation of the umbilicus and like-
wise reduce the risk of acquired infection. Prophylactic antibiotics
may be effective in preventing catheter-related blood stream infec-
tion (CRBSI), but may have the undesirable effect of promoting
the emergence of resistant strains of micro-organisms (Freij 1999).
A policy of prophylactic antibiotic use should take into account
this possibility, and has been used as a basis for arguing against
its implementation (Isaacs 2000; Isaacs 2003). Promotion of the
emergence of resistant strains of organisms may vary between dif-
ferent antibiotics.
A recent Cochrane systematic review on the use of prophylactic
antibiotics for neonates with umbilical artery catheters showed
that there is no evidence from randomised trials to support or
refute the use of prophylactic antibiotics when using umbilical
artery catheters in newborn infants (Inglis 2004).
O B J E C T I V E S
The primary objective was to assess whether prophylactic antibi-
otics, in neonates with umbilical venous catheters, reduce mortal-
ity and morbidity. Morbidity included proven septicaemia, clin-
ical septicaemia, and suspected septicaemia. Septicaemia was as
defined in individual studies.
In separate comparisons, we planned to review two different poli-
cies regarding the prophylactic use of antibiotics in neonates with
umbilical venous catheters:
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1) Among neonates with umbilical venous catheters, a policy of
prophylactic antibiotics for the duration of catheterisation (or
other fixed duration of antibiotic treatment) versus placebo or no
treatment. This addresses the question of whether or not neonates
with umbilical venous catheters, who do not have clinical or lab-
oratory evidence of infection at that time, should be routinely
started on antibiotics at the time of catheterisation.
2) Among neonates with umbilical venous catheters who had been
started on antibiotics at the time of catheterisation, but whose
initial cultures to rule out sepsis are negative, a policy of continuing
versus discontinuing prophylactic antibiotics. This addresses the
question of whether or not antibiotics should routinely be stopped
at the time rule out sepsis cultures are reported as negative.
Data permitting, subgroup analyses were planned to determine
whether results differ by:
gestational age (e.g. preterm versus term, < 28 weeks gestational
age (GA) or not);
type of antibiotic (e.g. penicillins, macrolides, aminoglycosides,
cephalosporins, or combinations).
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
We planned to include the following:
randomised controlled trials in which either individual newborn
infants or clusters of infants are randomised to receive prophylactic
antibiotics versus placebo or no treatment;
some types of non-randomised trials, i.e. quasi-randomised trials,
in which either individual newborn infants or clusters of infants
are allocated to receive prophylactic antibiotics versus placebo or
no treatment.
Trials where the unit of allocation is the catheter (in which case
different catheters within the same patient might be managed dif-
ferently) were not included.
Trials where the cluster unit is time were not included (as this
would not allow the assessment of antibiotic resistance).
Types of participants
Neonates with umbilical venous catheters. The standard definition
of “neonate” was used i.e. up to 28 days of age.
Types of intervention
Any antibiotic, or combination of antibiotics, versus placebo or no
treatment. This could include: 1) a policy of all neonates with um-
bilical venous catheters having antibiotics compared with placebo
or no treatment; or 2) a policy of neonates with umbilical venous
catheters continuing on antibiotics, once initial cultures to rule
out sepsis are negative, compared with ceasing antibiotics and con-
tinuing on placebo and/or no treatment.
Types of outcome measures
Primary:
• Mortality (neonatal, at hospital discharge, or at one year, eigh-
teen months, two years, or five years)
• Proven septicaemia (blood culture positive) or either suspected
septicaemia or clinical septicaemia (however defined in individ-
ual studies)
Septicaemia might occur more than once in the same patient and
may be reported in several different ways. We planned to tabulate
this as a categorical outcome (e.g. proportion of patients having
one or more
episodes)
Secondary:
• Chronic lung disease (oxygen requirement at 36 weeks post-
menstrual age)
• Duration of ventilation (hours or days)
• Duration of respiratory support (hours or days)
• Duration of oxygen therapy (hours or days)
• Duration of hospital stay (days)
• Number of resistant organisms (i.e. species) identified per time
period per infant or per cluster unit
• Neurodevelopmental outcome (cerebral palsy, sensorineural
hearing loss, visual impairment and/or developmental delay will
be considered as separate components - at one year, eighteen
months, two years, or five years)
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Neonatal Group methods used in reviews.
See: Cochrane Neonatal Review Group search strategy
The standard search strategy for the Cochrane Neonatal Review
Group was used. We searched MEDLINE from 1966 to April
2005, CINAHL from 1982 to April 2005, and the Cochrane
Central Register of Controlled Trials (CENTRAL, The Cochrane
Library, Issue 1, 2005) using the following strategy:
MeSH search terms (“Umbilicus” AND “Catheterization”) OR
the textwords (“umb$” AND (“cathet$” OR “cannul$”)) OR
“UVC” OR “umbilical vein catheter” OR “umbilical venous
catheter”
AND
MeSH search term “Infant, newborn” OR the textwords
“neonat$” OR “infant”’
AND
MeSH search term “Antibiotics” OR the textword “antibiotic”
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AND
MeSH search terms “Chemoprevention” OR “Antibiotic Prophy-
laxis” OR the textword “prophyl$”.
We also searched previous reviews (including cross references).
Searches were not restricted to publications in the English language
or published data.
M E T H O D S O F T H E R E V I E W
Criteria and methods used to assess the methodological quality of
the trials: standard methods of the Cochrane Collaboration and
its Neonatal Review Group were used.
The two authors worked independently to search for and assess tri-
als for inclusion and methodological quality. Studies were assessed
using the following key criteria: allocation concealment (blinding
of randomisation), blinding of intervention, completeness of fol-
low up and blinding of outcome measurement assigning a rating
of ’Yes’, ’No’ or ’Can’t tell’ for each. The authors extracted data
independently. Differences were resolved by discussion. We con-
tacted the second author of the study by Bhatt et al (Bhatt 1970)
for additional information or data.
For pooled results: for continuous variables, weighted mean differ-
ences (WMD) and 95% confidence intervals were to be reported.
For categorical outcomes, the relative risks (RR) and 95% confi-
dence intervals were to be reported. For significant findings, the
risk difference (RD) and number needed to treat (NNT) were also
to be reported. Each treatment effect was to be tested for hetero-
geneity to help determine suitability for pooling of results in a
meta-analysis. The fixed effects model was to be used for meta-
analysis. If there were sufficient included studies, heterogeneity
was to be assessed using the I squared test. If statistical heterogene-
ity was found the authors planned to look for an explanation. If
studies with heterogenous results were thought to be comparable,
a random effects model was to be used to combine the data.
Data permitting, a sensitivity analysis was planned to see if results
differed by quality of included studies i.e. adequacy of randomi-
sation - quasi randomised versus randomised.
D E S C R I P T I O N O F S T U D I E S
The search strategy identified four potentially eligible reports. Two
of the trials (Bard 1973; Cowett 1977) were excluded because they
were studies of infants with umbilical artery catheters. Another
(Bhatt 1970) was excluded because, as far as we could ascertain, it
was a study of arterial catheters. This study was published only in
Abstract form and involved 192 infants randomly assigned to treat-
ment (i.e. prophylactic antibiotics) and control groups. The pub-
lished abstract contained little methodological or outcome data.
We contacted one of the authors (JEH) and were advised that no
further data was available. The author advised also that, to her
knowledge, the study only involved infants with arterial catheters.
The study by Pulido et al (Pulido 1985) was included. The study
attempted to address the question of whether term infants with
umbilical venous catheters had lower rates of infection when
given antibiotic prophylaxis, compared with untreated controls.
The study was non-randomised (quasi-randomised, using alter-
nate group allocation), was small, of short duration, and involved
infants with very specific indications for umbilical venous catheter
insertion: i.e. catheters were inserted for transfusion procedures in
infants with hyperbilirubinaemia or polycythaemia. There was a
wide range of age at enrolment (1 - 10 days). Twenty-nine term
infants with umbilical venous catheters were allocated non-ran-
domly (quasi-randomised - alternate allocation) to treatment (n
= 15) or control (n = 14) groups. Those in the treatment group
received penicillin and gentamicin for three days, but no mention
is made of duration of catheterisation. It is possible that duration
of treatment exceeded duration of catheterisation or vice versa.
Two peripheral blood cultures were drawn from all study infants
three days after catheter insertion. Results were presented as num-
ber of positive blood cultures and number of true-positive blood
cultures.
M E T H O D O L O G I C A L Q U A L I T Y
There were significant methodological flaws in the only study iden-
tified (Pulido 1985) for inclusion in this review:
• the study was non-randomised (quasi-randomised, using alter-
nate group allocation);
• the intervention appears to have been non-blinded, but the
report is not explicit on this matter;
• it is unknown whether outcome assessment was blind;
• completeness of follow up is unclear;
• allocation concealment was not blinded.
R E S U L T S
One study (Pulido 1985) was included in this review.
For primary outcomes:
• Proven septicaemia - 5/15 intervention and 5/14 control infants
had positive blood cultures three days after UVC insertion. All
positive blood cultures were considered contaminated, due to
lack of corroborating clinical and haematological evidence of
infection. Therefore, no infants were identified with evidence
of septicaemia.
• Mortality - not assessed/reported
For secondary outcomes:
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• Chronic lung disease (oxygen requirement at 36 weeks post-
menstrual age) - not assessed/reported
• Duration of ventilation (hours or days) - not assessed/reported
• Duration of respiratory support (hours or days) - not assessed/
reported
• Duration of oxygen therapy (hours or days) - not assessed/re-
ported
• Duration of hospital stay (days) - not assessed/reported
• Number of resistant organisms - not assessed/reported
• Neurodevelopmental outcome - not assessed/reported
D I S C U S S I O N
This review has attempted to determine whether prophylactic an-
tibiotics are warranted in either of two circumstances:
1. Should infants with umbilical venous catheters be commenced
on routine prophylactic antibiotics at the time of catheter inser-
tion?
2. Should infants with umbilical venous catheters, who are com-
menced on antibiotics pending investigation results, be continued
on antibiotics once initial infection is ruled out?
A major limiting factor in trying to determine the place of prophy-
lactic antibiotics in infants with umbilical venous catheters is that
catheter placement is quite often undertaken, for ease of fluid and
drug administration, in the context of clinical circumstances (e.g.
respiratory distress, preterm delivery) which may reflect infection.
Newborn infants in such circumstances are usually commenced on
antibiotics because their clinical circumstances may indicate infec-
tion at the same time that they may lead to the decision to insert
an umbilical venous catheter. Because the majority of newborns
in whom umbilical venous catheters are placed would be treated
in this way, the first scenario described above would be relevant
to relatively few newborns. The second scenario described above
would be the more common one encountered.
One non-randomised (quasi-randomised) trial was found for in-
clusion in this review. Pulido et al (Pulido 1985) performed a small
study on the use of antibiotic prophylaxis in infants undergoing
transfusion procedures for hyperbilirubinaemia or polycythaemia
via an umbilical venous catheter. The authors conclude that no
infant in the study developed septicaemia following the procedure,
and that the use of antibiotic prophylaxis is not indicated. A study
of this size would have been underpowered to detect anything
other than a very large effect. The study covered a period of only
two months. It has been noted previously that nosocomial infec-
tions can occur in clusters (Adams-Chapman 2002). If the study
under consideration here coincided with a nadir in nosocomial in-
fection, then the resultant underestimation of septicaemia rates in
one or both arms of the study could have affected the conclusions.
It is difficult to generalise the findings of this study for a number of
reasons. Since its publication there have been significant changes in
the practice of neonatal medicine, including use and maintenance
of vascular access devices. The use of umbilical venous catheters
in this study was for specific indications and the background risk
of infection in the study subjects may have been low. The average
age at catheter insertion in this study was probably significantly
greater than would be seen in most units today. Given the poor
methodological quality of the study, we cannot rely on the results
provided with regard to effects on infection rates.
Quasi-randomised trials are inherently prone to bias, and their
results should be interpreted with caution. The alternate group
assignment makes the upcoming treatment group allocation pre-
dictable, and that is a problem in the case of every eligible infant.
Also, if two equally eligible infants present at the same time with
different risks for infection a clinician might (consciously or not)
enter them into the study in the order that would allow the infant
that they believed should receive antibiotics to get antibiotics. If a
large number of infants were enrolled in this way, serious imbal-
ance in the treatment groups with respect to factors affecting the
outcome would result (Hennekens 1987).
In order to justify the use of prophylactic antibiotics (rather than
treatment of infection as it arises) in infants with umbilical venous
catheters, there should be evidence that the benefit outweighs the
harm. This should include an adequate assessment not only of
short term outcomes such as infection rate and duration of hospital
admission, but also of long term outcomes such as mortality, long
term respiratory morbidity and neurodevelopmental outcome.
Theoretical concerns about the potential harm of prophylactic an-
tibiotic use include emergence of resistant strains of bacteria, su-
perinfection and drug toxicity. Altered antibiotic resistance pat-
terns may be of consequence not only to the individual in whom
prophylactic antibiotics are used but also to other patients within
the hospital setting and to the broader community.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• There is insufficient evidence from published clinical trials to
support or refute the use of prophylactic antibiotics when in-
serting umbilical venous catheters in newborn infants.
• There is no evidence from clinical trials to support or refute
continuing antibiotics once initial cultures rule out infection in
newborn infants with umbilical venous catheters.
Implications for research
• If prophylactic antibiotics are to be considered when inserting
umbilical venous catheters, then good quality randomised con-
trolled trials are required to show that their benefits outweigh
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the harms. Unfortunately, most newborn infants who have um-
bilical venous catheters inserted are likely to receive antibiotics
to cover possible infection and a randomised controlled trial
may not be practicable or ethical.
• A more pressing question is whether infants who initially re-
ceive antibiotics for presumed infection should be continued on
antibiotics once initial cultures rule out infection. Good quality
randomised controlled trials are required to address this issue.
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T A B L E S
Characteristics of included studies
Study Pulido 1985
Methods This non-randomised (quasi-randomised - alternate allocation) study took place between July and August
1984 at a regional neonatal intensive care unit in Chile. Enrolled infants were allocated alternately into
intervention and control groups. All subjects had 2 peripheral blood cultures and a full blood count (FBC)
drawn three days following the procedure. At this stage antibiotics were discontinued if there was deemed to be
no clinical or laboratory (i.e. FBC) evidence of infection. Blood cultures were read at 7 days. Septicaemia was
defined as positive blood culture combined with clinical and laboratory evidence of infection. Intervention
was probably not blinded. Completeness of follow up is not addressed. It is unclear whether outcome
assessment was blinded.
Participants Twenty-nine infants were studied. All were term. Twenty-three underwent exchange transfusion for hyper-
bilirubinaemia, and 6 underwent globuloforesis (partial exchange transfusion) for haematocrit greater than
0.70. All infants had their procedures performed via umbilical venous catheter. Infants requiring repeat pro-
cedures were excluded from the study (the number of such infants, if any, is not specified). There were 15
infants in the intervention group and 14 in the control group.
Interventions Infants in the intervention group (n = 15) received penicillin and gentamicin for 3 days following the
procedure. Control infants (n = 14) received no antibiotics. No placebo was used. Other care was similar.
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Characteristics of included studies (Continued )
Outcomes Septicaemia: based on positive blood culture (3 days after UVC insertion) in conjunction with clinical and
haematological evidence of infection.
Notes
Allocation concealment D
FBC = full blood count and examination
UVC = umbilical venous catheter
Characteristics of excluded studies
Bard 1973 Study of umbilical artery catheters.
Bhatt 1970 Published in Abstract form only. The second author was contacted and could offer no further data, except that the
study involved infants with arterial, rather than venous, catheters.
Cowett 1977 Study of umbilical artery catheters.
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Analysis 01.01. Comparison 01 Prophylactic antibiotics versus no antibiotics, Outcome 01 Septicaemia
Review: Prophylactic antibiotics to reduce morbidity and mortality in neonates with umbilical venous catheters
Comparison: 01 Prophylactic antibiotics versus no antibiotics
Outcome: 01 Septicaemia
Study Antibiotics Control Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
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